ImmuCell (NASDAQ:ICCC) Issues Earnings Results

ImmuCell (NASDAQ:ICCC) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16, FiscalAI reports. ImmuCell had a negative return on equity of 3.60% and a negative net margin of 3.76%.The firm had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.40 million.

ImmuCell Trading Up 8.0%

ICCC traded up $0.66 during midday trading on Friday, hitting $8.92. 60,599 shares of the company were exchanged, compared to its average volume of 20,868. The firm has a market capitalization of $80.73 million, a P/E ratio of -81.08 and a beta of 0.50. ImmuCell has a 1-year low of $4.52 and a 1-year high of $9.08. The firm’s 50 day moving average price is $7.20 and its 200-day moving average price is $6.44. The company has a quick ratio of 1.93, a current ratio of 4.26 and a debt-to-equity ratio of 0.28.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC increased its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,852 shares of the biotechnology company’s stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. 13.47% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ImmuCell currently has an average rating of “Sell”.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.